Water retention Temporary fluid retention during initial weeks, more common with the DAC formulation
Arumugama, V., Haugabrooks, E., Williamson, P., and Hendrich, S
Smolen, J
Internal standard mix (final concentration 0.5 g ml 1 ) included: N-palmitoyl-d31- d -erythro-sphingosine (C16-d31 ceramide), pentadecanoic-d29 acid (15:0-d29 free fatty acid (FFA)), heptadecanoic-d33 acid (17:0-d33 FFA), eicosanoic-d39 acid (20:0-d39 FFA), tetradecylphosphatidylcholine-d42 (14:0-d29 LPC-d13), 1-palmitoyl(d31)-2-oleyl- sn -glycero-3-phosphatidylcholine (16:0-d3118:1 PC), 1-palmitoyl(d31)-2-oleyl- sn -glycero-3-phosphoethanolamine (16:0-d3118:1 PE), 1-palmitoyl-d312-oleoyl- sn -glycero-3-[phospho-rac-(1-glycerol)] (16:0-d3118:1 PG), 1-palmitoyl-d312-oleoyl- sn -glycero-3-phosphoinositol (16:0-d3118:1 PI), N-palmitoyl(d31)- d -erythro-sphingosylphosphorylcholine (16:0-d31 SM), glyceryl-tri(pentadecanoate-d29) (45:0-d87 TAG), glyceryl-tri(hexadecanoate-d31) (48:0-d93 TAG) (all from Avanti Polar Lipids)

It is commonly classified as tachycardia (supraventricular or ventricular) or bradycardia, with clinical manifestations varying according to the type, cardiac function, and degree of hemodynamic impact